Miruvor
Sign up
The short answer

What studies of Nifedipine (Procardia, Adalat) found

2papers on Nifedipine (Procardia, Adalat)
1 (few people)person in 1 study testing Nifedipine (Procardia, Adalat) alone
0randomised trials, the strongest kind of study

At a glance, by condition

ME/CFS: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 5 findings, all C.

5 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Nifedipine (Procardia, Adalat) might help some people with ME/CFS, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 2 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Nifedipine (Procardia, Adalat) · ME/CFS is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

ME/CFS

Symptoms

Cognition (brain fog)1 study · 1 (few people) person took Nifedipine (Procardia, Adalat) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · After five days · 10 mg three times/day (few people)

Cognition (brain fog) improved.

The evidence is very uncertain about the effect of nifedipine (Procardia, Adalat) on cognition (brain fog) in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Chronic fatigue syndrome: possible effective treatment with nifedipine. (1988)

    People in the study
    1 in the study
    Dose
    10 mg three times/day
    Outcome
    level of attention, mental organization, and memory retention
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 1 (few people) person took Nifedipine (Procardia, Adalat) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · After five days · 10 mg three times/day (few people)

Fatigue improved.

The evidence is very uncertain about the effect of nifedipine (Procardia, Adalat) on fatigue in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Chronic fatigue syndrome: possible effective treatment with nifedipine. (1988)

    People in the study
    1 in the study
    Dose
    10 mg three times/day
    Outcome
    excessive fatigability
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Pain1 study · 1 (few people) person took Nifedipine (Procardia, Adalat) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · After five days · 10 mg three times/day (few people)

Pain improved.

The evidence is very uncertain about the effect of nifedipine (Procardia, Adalat) on pain in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Chronic fatigue syndrome: possible effective treatment with nifedipine. (1988)

    People in the study
    1 in the study
    Dose
    10 mg three times/day
    Outcome
    headache
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Daily functioning1 study · 1 (few people) person took Nifedipine (Procardia, Adalat) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · After five days · 10 mg three times/day (few people)

Daily functioning improved.

The evidence is very uncertain about the effect of nifedipine (Procardia, Adalat) on daily functioning in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Chronic fatigue syndrome: possible effective treatment with nifedipine. (1988)

    People in the study
    1 in the study
    Dose
    10 mg three times/day
    Outcome
    functional status (education/work)
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 1 (few people) person took Nifedipine (Procardia, Adalat) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · After five days · 10 mg three times/day (few people)

Overall symptoms improved.

The evidence is very uncertain about the effect of nifedipine (Procardia, Adalat) on overall symptoms in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Chronic fatigue syndrome: possible effective treatment with nifedipine. (1988)

    People in the study
    1 in the study
    Dose
    10 mg three times/day
    Outcome
    symptom resolution after restarting nifedipine
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Side effects

No study of this treatment alone reported side effects we could read.

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    10 to 30 mg at the start

  2. 2Top dose

    Most often 10 mg (1 of 2 studies)

Doses across 2 studies

10 to 30 mg.

Each study’s dose, as printed

All papers

  1. Successful Ivabradine Use Throughout Pregnancy for Postural Orthostatic Tachycardia Syndrome: A Case Report with Reassuring Maternal-Fetal Outcomes2026 · case report · 1 in the study
    Summary

    This case report describes one 35-year-old gravida 2 para 1 woman with long-COVID postural orthostatic tachycardia syndrome (POTS) who had recurrent emergency department visits and cardiac intensive care admissions for orthostatic palpitations. During her second pregnancy she continued all pharmacologic therapies from preconception through delivery at 38 weeks 5 days: ivabradine 12.5 mg twice daily, propranolol 40 mg 4 times daily, midodrine 15 mg 3 times daily, methyldopa 125 mg nightly, and extended-release nifedipine 30 mg once daily. The report compares her course with her first pregnancy, when cardiac medications were discontinued. Enhanced fetal surveillance included serial nonstress testing, growth studies and fetal Dopplers. Fetal assessments were reassuring throughout gestation, with no evidence of fetal bradycardia, arrhythmia or structural abnormalities, and no evidence of sustained bradycardia or fetal growth restriction. She reported improved symptom control and functional capacity compared with her first pregnancy. At 38 weeks 5 days' gestation an elective repeat low-transverse caesarean delivery occurred without complication; a healthy female neonate was delivered with Apgar scores of 9 and 9, and cord blood gases, newborn examination and standard neonatal screening results were normal. The authors state the polypharmacy confounds attribution of outcomes solely to ivabradine and that maternal hemodynamic data are not presented.

  2. Chronic fatigue syndrome: possible effective treatment with nifedipine.1988 · case report · 1 in the study
    Summary

    This paper reports a case of a 20-year-old man with chronic fatigue syndrome. He first presented to the author with pharyngitis, periorbital edema, leg pain, and blurred vision. He was given nifedipine 10 mg three times/day; duration and route were not reported. There was no comparison group, randomisation, or crossover. After five days, his headache abated and his family noticed a marked increase in his level of attention, mental organization, and memory retention and, most prominently, no excessive fatigability. He left home without his nifedipine during a family crisis, and after three days the symptoms recurred; after restarting nifedipine the symptoms disappeared in 72 hours. On several occasions when he did not take nifedipine, symptoms returned within 72 hours. Currently, the patient is still taking nifedipine treatment and shows continued improvement. He has completed a high school general equivalency diploma, works part-time, and is currently enrolled in a junior college. Harms and withdrawals were not reported. The authors state that continuing the medication seems to prevent the symptoms, but the reason for the efficacy of nifedipine in this situation is unknown. They state that whether nifedipine's ability to ameliorate this patient's symptoms can be duplicated in other patients with the chronic fatigue syndrome will depend on further clinical trials.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime